HMBD-001
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for HMBD-001, covering 2025-04-18 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers [Phase 1, Phase 2]